{"id":816693,"date":"2025-02-24T10:30:28","date_gmt":"2025-02-24T15:30:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\/"},"modified":"2025-02-24T10:30:28","modified_gmt":"2025-02-24T15:30:28","slug":"pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\/","title":{"rendered":"PDS Biotech Announces Circulating Tumor DNA Results for Versamune\u00ae HPV in IMMUNOCERV Trial Published in Clinical Cancer Research"},"content":{"rendered":"
\n

\n Data confirms Versamune<\/em>
\n
\n \u00ae<\/em>
\n <\/sup>
\n HPV has potential as a broadly effective treatment of HPV16-associated cancers \u2013\u00a0Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025<\/em>\n <\/p>\n

\n Versamune<\/em>
\n
\n \u00ae<\/em>
\n <\/sup>
\n HPV + CRT was associated with greater and earlier clearance of blood-circulating HPV16-positive cancer cells (circulating tumor DNA\/ctDNA) vs. CRT alone<\/em>\n <\/p>\n

\n 100% of patients with locally advanced HPV16 cervical cancer treated with Versamune<\/em>
\n
\n \u00ae<\/em>
\n <\/sup>
\n HPV + CRT had no detectable HPV16 ctDNA at 3-4 months vs. 50% of patients on standard-of-care CRT<\/em>\n <\/p>\n

\n Undetectable HPV ctDNA at 3-4 months was associated with improved 2-year recurrence-free survival (RFS) of 93% vs only 30% in patients with detectable HPV ctDNA <\/em>\n <\/p>\n

PRINCETON, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (\u201cPDS Biotech\u201d or the \u201cCompany\u201d), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the publication of circulating tumor DNA (ctDNA) results for its lead immunotherapy candidate, Versamune\u00ae<\/sup> HPV, in Clinical Cancer Research<\/em><\/a>, a journal of the American Association for Cancer Research.<\/p>\n

The trial demonstrated that Versamune\u00ae<\/sup> HPV was associated with greater and earlier clearance of HPV16-positive cancer cells from the bloodstream in patients with locally advanced cervical cancer. Notably, the elimination of HPV16-positive ctDNA correlated with extended patient survival without cancer recurrence, reinforcing its potential to improve long-term outcomes. The data underscore the potential of Versamune\u00ae<\/sup> HPV in HPV16-positive cancers as the Company prepares to initiate a Phase 3 clinical trial for Versamune\u00ae<\/sup> HPV in HPV16-positive head and neck squamous cell carcinoma (HNSCC) in the first quarter of this year.<\/p>\n

\u201cThese findings highlight the transformative potential of Versamune\u00ae<\/sup> HPV in broadly treating various HPV16-associated cancers. Combining Versamune\u00ae <\/sup>HPV with chemoradiation (CRT) was linked to rapid HPV16 ctDNA decline,\u201d said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech. \u201cWe believe that such results showing a strong correlation between a biomarker such as ctDNA and survival may allow us to initiate discussions with the U.S. Food and Drug Administration regarding the potential for an accelerated regulatory pathway such as Breakthrough Therapy designation in cervical cancer. We also think this finding that links the reduction of ctDNA level with improved survival may apply to other HPV16-positive cancers like HNSCC. This endpoint is currently included within our VERSATILE-003 Phase 3 clinical trial.\u201d<\/p>\n

A total of 66 patients with locally advanced cervical cancer were enrolled, with 49 receiving CRT and 17 receiving a combination of CRT and Versamune\u00ae<\/sup> HPV. Patient blood was collected at baseline, weeks 1, 3, and 5 of CRT, and 3 to 4 months after CRT to measure HPV ctDNA. MRI was performed at baseline and before brachytherapy to determine tumor shrinkage.<\/p>\n

Median follow-up was 23 months. At 3-4 months follow-up, 5\/5 (100%) HPV16-positive patients receiving CRT + Versamune\u00ae <\/sup>HPV had no detectable HPV16-positive ctDNA, whereas 3\/6 (50%) of patients receiving only CRT had no detectable ctDNA.<\/p>\n

HPV ctDNA clearance at 3-4 months correlated with better 2-year recurrence free survival (RFS) (92.9% vs. 30%, log-rank;\u00a0P<\/em>\u00a0= 0.0067). The strongest predictor of RFS was HPV ctDNA clearance at 3-4 months follow-up, achieving a concordance index score of 0.83.<\/p>\n

The 36-month overall survival (OS) and progression free survival rates were earlier reported to be 100% for the 8 patients in the trial who received 5 doses of Versamune\u00ae<\/sup> HPV + CRT and an 84.4% 36-month OS rate for 17 patients who received at least 2 doses of Versamune\u00ae<\/sup> HPV + CRT.<\/p>\n

\n About PDS Biotechnology
<\/strong>PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The Company plans to initiate a pivotal clinical trial to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech\u2019s lead investigational targeted immunotherapy Versamune\u00ae<\/sup> HPV is being developed in combination with a standard-of-care immune checkpoint inhibitor, and also in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor.<\/p>\n

For more information, please visit www.pdsbiotech.com<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the \u201cCompany\u201d) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company\u2019s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cplan,\u201d \u201clikely,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cforecast,\u201d \u201cguidance\u201d, \u201coutlook\u201d and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company\u2019s ability to protect its intellectual property rights; the Company\u2019s anticipated capital requirements, including the Company\u2019s anticipated cash runway and the Company\u2019s current expectations regarding its plans for future equity financings; the Company\u2019s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company\u2019s operations or require the Company to relinquish rights to the Company\u2019s technologies or product candidates; the Company\u2019s limited operating history in the Company\u2019s current line of business, which makes it difficult to evaluate the Company\u2019s prospects, the Company\u2019s business plan or the likelihood of the Company\u2019s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for Versamune\u00ae<\/sup>\u00a0HPV, PDS01ADC and other Versamune\u00ae<\/sup>\u00a0based product candidates; the future success of such trials; the successful implementation of the Company\u2019s research and development programs and collaborations, including any collaboration studies concerning Versamune\u00ae<\/sup>\u00a0HPV, PDS01ADC and other Versamune\u00ae<\/sup>\u00a0based product candidates and the Company\u2019s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company\u2019s product candidates; the success, timing and cost of the Company\u2019s ongoing clinical trials and anticipated clinical trials for the Company\u2019s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company\u2019s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company\u2019s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company\u2019s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company\u2019s ability to continue as a going concern; and other factors, including legislative, regulatory, political and economic developments not within the Company\u2019s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under \u201cRisk Factors,\u201d \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n

Versamune\u00ae<\/sup>\u00a0is a registered trademark of PDS Biotechnology Corporation.<\/p>\n

\n Investor Contact:<\/strong>
\n
Mike Moyer
LifeSci Advisors
Phone +1 (617) 308-4306
Email: mmoyer@lifesciadvisors.com<\/a><\/p>\n

\n Media Contact:<\/strong>
\n
Janine McCargo
6 Degrees
Phone +1 (646) 528-4034
Email:\u00a0jmccargo@6degreespr.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Data confirms Versamune \u00ae HPV has potential as a broadly effective treatment of HPV16-associated cancers \u2013\u00a0Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025 Versamune \u00ae HPV + CRT was associated with greater and earlier clearance of blood-circulating HPV16-positive cancer cells (circulating tumor DNA\/ctDNA) vs. CRT alone 100% of patients with locally advanced HPV16 cervical cancer treated with Versamune \u00ae HPV + CRT had no detectable HPV16 ctDNA at 3-4 months vs. 50% of patients on standard-of-care CRT Undetectable HPV ctDNA at 3-4 months was associated with improved 2-year recurrence-free survival (RFS) of 93% vs only 30% in patients with detectable HPV ctDNA PRINCETON, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (\u201cPDS … <\/p>\n

Continue reading “PDS Biotech Announces Circulating Tumor DNA Results for Versamune\u00ae HPV in IMMUNOCERV Trial Published in Clinical Cancer Research”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-816693","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPDS Biotech Announces Circulating Tumor DNA Results for Versamune\u00ae HPV in IMMUNOCERV Trial Published in Clinical Cancer Research - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PDS Biotech Announces Circulating Tumor DNA Results for Versamune\u00ae HPV in IMMUNOCERV Trial Published in Clinical Cancer Research - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Data confirms Versamune \u00ae HPV has potential as a broadly effective treatment of HPV16-associated cancers \u2013\u00a0Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025 Versamune \u00ae HPV + CRT was associated with greater and earlier clearance of blood-circulating HPV16-positive cancer cells (circulating tumor DNA\/ctDNA) vs. CRT alone 100% of patients with locally advanced HPV16 cervical cancer treated with Versamune \u00ae HPV + CRT had no detectable HPV16 ctDNA at 3-4 months vs. 50% of patients on standard-of-care CRT Undetectable HPV ctDNA at 3-4 months was associated with improved 2-year recurrence-free survival (RFS) of 93% vs only 30% in patients with detectable HPV ctDNA PRINCETON, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (\u201cPDS … Continue reading "PDS Biotech Announces Circulating Tumor DNA Results for Versamune\u00ae HPV in IMMUNOCERV Trial Published in Clinical Cancer Research"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-24T15:30:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjY3NyM2NzYyODcyIzIwMTcxODg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"PDS Biotech Announces Circulating Tumor DNA Results for Versamune\u00ae HPV in IMMUNOCERV Trial Published in Clinical Cancer Research\",\"datePublished\":\"2025-02-24T15:30:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\\\/\"},\"wordCount\":1364,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MjY3NyM2NzYyODcyIzIwMTcxODg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\\\/\",\"name\":\"PDS Biotech Announces Circulating Tumor DNA Results for Versamune\u00ae HPV in IMMUNOCERV Trial Published in Clinical Cancer Research - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MjY3NyM2NzYyODcyIzIwMTcxODg=\",\"datePublished\":\"2025-02-24T15:30:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MjY3NyM2NzYyODcyIzIwMTcxODg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MjY3NyM2NzYyODcyIzIwMTcxODg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PDS Biotech Announces Circulating Tumor DNA Results for Versamune\u00ae HPV in IMMUNOCERV Trial Published in Clinical Cancer Research\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PDS Biotech Announces Circulating Tumor DNA Results for Versamune\u00ae HPV in IMMUNOCERV Trial Published in Clinical Cancer Research - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\/","og_locale":"en_US","og_type":"article","og_title":"PDS Biotech Announces Circulating Tumor DNA Results for Versamune\u00ae HPV in IMMUNOCERV Trial Published in Clinical Cancer Research - Market Newsdesk","og_description":"Data confirms Versamune \u00ae HPV has potential as a broadly effective treatment of HPV16-associated cancers \u2013\u00a0Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025 Versamune \u00ae HPV + CRT was associated with greater and earlier clearance of blood-circulating HPV16-positive cancer cells (circulating tumor DNA\/ctDNA) vs. CRT alone 100% of patients with locally advanced HPV16 cervical cancer treated with Versamune \u00ae HPV + CRT had no detectable HPV16 ctDNA at 3-4 months vs. 50% of patients on standard-of-care CRT Undetectable HPV ctDNA at 3-4 months was associated with improved 2-year recurrence-free survival (RFS) of 93% vs only 30% in patients with detectable HPV ctDNA PRINCETON, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (\u201cPDS … Continue reading \"PDS Biotech Announces Circulating Tumor DNA Results for Versamune\u00ae HPV in IMMUNOCERV Trial Published in Clinical Cancer Research\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-24T15:30:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjY3NyM2NzYyODcyIzIwMTcxODg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"PDS Biotech Announces Circulating Tumor DNA Results for Versamune\u00ae HPV in IMMUNOCERV Trial Published in Clinical Cancer Research","datePublished":"2025-02-24T15:30:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\/"},"wordCount":1364,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjY3NyM2NzYyODcyIzIwMTcxODg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\/","name":"PDS Biotech Announces Circulating Tumor DNA Results for Versamune\u00ae HPV in IMMUNOCERV Trial Published in Clinical Cancer Research - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjY3NyM2NzYyODcyIzIwMTcxODg=","datePublished":"2025-02-24T15:30:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjY3NyM2NzYyODcyIzIwMTcxODg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjY3NyM2NzYyODcyIzIwMTcxODg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial-published-in-clinical-cancer-research\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"PDS Biotech Announces Circulating Tumor DNA Results for Versamune\u00ae HPV in IMMUNOCERV Trial Published in Clinical Cancer Research"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816693","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=816693"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816693\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=816693"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=816693"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=816693"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}